Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Inks New Pact To Synthesize Compounds For AstraZeneca

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Shanghai-headquartered WuXi PharmaTech, one of China's leading contract research organizations, this week signed a new agreement to synthesize compounds according to AstraZeneca's designs

You may also be interested in...



AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

AstraZeneca Shares Its Recipe For Partnering Success In Asia

Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane

Venturepharm Rides Chinese Wave Of CRO Growth; Sees Challenges Ahead As Competition Among MNCs, Locals Increase

HONG KONG - The growth of contract research organizations in China has been little short of astounding. China has overtaken India as one of the fastest-growing locations for drug trials, leveraging a huge population and Western-trained doctors into a competitive industry

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel